11 Best Cancer Stocks to Buy Right Now

5. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 39 

Moderna, Inc. (NASDAQ:MRNA) stands fifth among the best cancer stocks. It is best known for its mRNA COVID-19 vaccine and is expanding into oncology with a focus on personalized cancer immunotherapies. The company’s strategy centers on using mRNA technology to encode tumor-specific antigens, training the immune system to recognize and destroy cancer cells.

A major milestone in 2025 is the Phase 1 trial of mRNA-4106, a pan-tumor antigen therapy for advanced solid tumors, launched in partnership with the START Center for Cancer Research. This therapy encodes multiple shared tumor antigens, aiming to broaden treatment beyond single-target approaches. The trial is testing mRNA-4106 alone and in combination with checkpoint inhibitors to evaluate safety, immune activation, and early efficacy.

In parallel, Moderna, Inc. (NASDAQ:MRNA) is advancing its personalized cancer vaccine (PCV) platform, developed with Merck, which tailors mRNA vaccines to individual tumor mutations identified via next-generation sequencing. These vaccines are rapidly manufactured in small batches and combined with immunotherapies like Keytruda to improve patient outcomes. Several PCV candidates are in late-stage development, including Phase 3 trials for melanoma, one of the firm’s most closely watched programs.

Upcoming clinical data, particularly from melanoma studies, could provide the foundation for regulatory filings and commercial launch in the coming years. If successful, Moderna, Inc. (NASDAQ:MRNA)’s PCV could represent a breakthrough in cancer treatment, establishing mRNA as a versatile technology for both infectious disease and oncology.